A protein in tumor tissue may help predict how glioblastoma will go
Original title: Intercellular adhesion molecule 1 links glioblastoma biology to a scalable prognostic model integrating clinical, imaging, and molecular features.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was studied by looking back at tumor samples and scans from patients, not in a trial of a treatment.
The short version
A common lab stain, a routine scan, and a person's age together may give a better picture of how a glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary will behave.
What was studied. Researchers studied tumor samples and scans from people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary (the IDH-wildtype kind) at more than one hospital. None had been treated yet. The team measured a protein called ICAM1 in the tumor, looked at gene activity, and measured the shape of the tumor on MRI scans.
What they found. Tumors with high ICAM1 were linked to shorter survival. That link was strongest in one tumor subtype called mesenchymal. High ICAM1 tumors also showed more signs of inflammation, low oxygen, stress, and immune cells that hold back the body's defenses. ICAM1 level, how ragged the tumor's edge looked on the scan, and the person's age each predicted outcome on their own. Put together, they predicted outcomes better across separate groups of patients.
What this means, and what it doesn't
What it could mean: This could help doctors give a more accurate picture of what to expect. It uses tests many hospitals already have, like a standard tissue stain and a normal MRI. That may help most in places that cannot do advanced molecular testing.
What it doesn't mean: This is not a treatment. It does not slow or shrink the tumor, and it is not a cure or a promise of one. The researchers looked back at tissue and scans that already existed. They did not run a trial to see if using this tool helps people live longer or feel better. It is not part of everyday care yet, and more work is needed before it could be.
Source: PubMed, July 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.